When magnetic resonance imaging (MRI) did not provide a clear answer in suspected prostate cancer, the use of PSMA-PET/CT showed promise. This method reduces the number of necessary biopsies without the risk of missing important forms of cancer. PSMA-PET/CT uses prostate-specific membrane antigen for imaging. This is an advance in diagnosis, especially when standard methods fail. The study confirmed that PSMA-PET/CT allows avoiding biopsy in patients with equivocal findings from MRI. The diagnosis of significant malignancies thus remains reliable. [](https://medpagetoday.com)